U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SEC File Number 0-30641
CUSIP Number 50172 A
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
[ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR
For Period Ended: September 30, 2002
_________________________________
Nothing in this Form shall be construed to imply that the Commission has
verified any information contained herein.
_________________________________
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates: N/A
_________________________________
Part I - Registrant Information
_________________________________
Full Name of Registrant: L.A.M. Pharmaceutical, Corp.
Former Name if Applicable: N/A.
Address of Principal Executive Office (Street and Number)
800 Sheppard Avenue West
Commercial Unit 1
City, State and Zip Code
North Ontario
Canada M3H 6B4
_________________________________
Part II - Rules 12b-25(b) and (c)
_________________________________
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this form could
not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, or transition report
or portion thereof will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly report or transition
report on Form l0-Q or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
_________________________________
Part III - Narrative
_________________________________
State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K,
10-Q, or N-SAR, or the transition report or portion thereof could not be filed
within the prescribed time period.
On November 14, 2002 the Company's Chief Executive and Financial Officer
was traveling and away from the Company's principal executive office. As a
result, he did not have time to review and sign the report in sufficient time so
as to permit the filing of the report by 5:30 p.m. Eastern time on November 14,
2002.
_________________________________
Part IV - Other Information
_________________________________
(1) Name and telephone number of person to contact in regard to this
notification
William T. Hart (303) 839-0061
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding l2 months (or for such
shorter period that the registrant was required to file such reports) been
filed? If answer is no, identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? [ ] Yes [X] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
L.A.M. Pharmaceutical Corp.
------------------------------
(Name of Registrant as specified in charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: November 14, 2002 By /s/ William T. Hart
------------------------
William T. Hart
Attorney for L.A.M. Pharmaceutical Corp.
1624 Washington Street
Denver, CO 80203
(303) 839-0061
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).